Cargando…

Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients

BACKGROUND: The high failure rates of metal on metal (MoM) large diameter head total hip arthroplasty (LDH THA) and hip resurfacing (HR) prevented their long-term comparisons with regards to clinical outcome. Such knowledge would be important as ceramic LDH bearing is now available. With long-term f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostretzis, Lazaros, Lavigne, Martin, Kiss, Marc-Olivier, Shahin, Maged, Barry, Janie, Vendittoli, Pascal-André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091753/
https://www.ncbi.nlm.nih.gov/pubmed/33941155
http://dx.doi.org/10.1186/s12891-021-04286-6
_version_ 1783687542564978688
author Kostretzis, Lazaros
Lavigne, Martin
Kiss, Marc-Olivier
Shahin, Maged
Barry, Janie
Vendittoli, Pascal-André
author_facet Kostretzis, Lazaros
Lavigne, Martin
Kiss, Marc-Olivier
Shahin, Maged
Barry, Janie
Vendittoli, Pascal-André
author_sort Kostretzis, Lazaros
collection PubMed
description BACKGROUND: The high failure rates of metal on metal (MoM) large diameter head total hip arthroplasty (LDH THA) and hip resurfacing (HR) prevented their long-term comparisons with regards to clinical outcome. Such knowledge would be important as ceramic LDH bearing is now available. With long-term follow-up, we investigated the difference in 1) patient-reported outcome measures (PROMs); 2) revision and adverse events rates, and 3) metal ion levels between MoM LDH THA and HR. METHODS: Forty-eight patients were randomized for LDH THA (24) or HR (24) with the same MoM articulation. At a mean follow-up of 14 years, we compared between groups different PROMs, the number of revisions and adverse events, whole blood Cobalt (Co) and Chromium (Cr) ion levels, and radiographic signs of implant dysfunction. RESULTS: LDH THA (all cases: revised and well-functioning) had significantly better WOMAC (94 versus 85, p = 0.04), and more frequently reported having no limitation (p = 0.04). LDH THA revision rate was 20.8% (5/24) versus 8.3% (2/24) for HR (p = 0.4). Mean Co and Cr ion levels were higher in LDH THA compared to the HR (Co: 3.8 μg/L vs 1.7 μg/L; p = 0.04 and Cr: 1.9 μg/L vs 1.4 μg/L, p = 0.1). On radiographic analyses, 2 LDH THAs showed signs of adverse reaction to metal debris, whereas 1 loose femoral HR component was documented. CONCLUSION: In the long-term, MoM LDH THA had a high trunnion related revision rate but nonetheless showed better PROMs compared to HR. Provided with a well-functioning modular junction, non-MoM LDH THA would offer an appealing option. TRIAL REGISTRATION: ClinicalTrials.gov (NCT04516239), August 18, 2020. Retrospectively registered.
format Online
Article
Text
id pubmed-8091753
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80917532021-05-04 Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients Kostretzis, Lazaros Lavigne, Martin Kiss, Marc-Olivier Shahin, Maged Barry, Janie Vendittoli, Pascal-André BMC Musculoskelet Disord Research Article BACKGROUND: The high failure rates of metal on metal (MoM) large diameter head total hip arthroplasty (LDH THA) and hip resurfacing (HR) prevented their long-term comparisons with regards to clinical outcome. Such knowledge would be important as ceramic LDH bearing is now available. With long-term follow-up, we investigated the difference in 1) patient-reported outcome measures (PROMs); 2) revision and adverse events rates, and 3) metal ion levels between MoM LDH THA and HR. METHODS: Forty-eight patients were randomized for LDH THA (24) or HR (24) with the same MoM articulation. At a mean follow-up of 14 years, we compared between groups different PROMs, the number of revisions and adverse events, whole blood Cobalt (Co) and Chromium (Cr) ion levels, and radiographic signs of implant dysfunction. RESULTS: LDH THA (all cases: revised and well-functioning) had significantly better WOMAC (94 versus 85, p = 0.04), and more frequently reported having no limitation (p = 0.04). LDH THA revision rate was 20.8% (5/24) versus 8.3% (2/24) for HR (p = 0.4). Mean Co and Cr ion levels were higher in LDH THA compared to the HR (Co: 3.8 μg/L vs 1.7 μg/L; p = 0.04 and Cr: 1.9 μg/L vs 1.4 μg/L, p = 0.1). On radiographic analyses, 2 LDH THAs showed signs of adverse reaction to metal debris, whereas 1 loose femoral HR component was documented. CONCLUSION: In the long-term, MoM LDH THA had a high trunnion related revision rate but nonetheless showed better PROMs compared to HR. Provided with a well-functioning modular junction, non-MoM LDH THA would offer an appealing option. TRIAL REGISTRATION: ClinicalTrials.gov (NCT04516239), August 18, 2020. Retrospectively registered. BioMed Central 2021-04-30 /pmc/articles/PMC8091753/ /pubmed/33941155 http://dx.doi.org/10.1186/s12891-021-04286-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kostretzis, Lazaros
Lavigne, Martin
Kiss, Marc-Olivier
Shahin, Maged
Barry, Janie
Vendittoli, Pascal-André
Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title_full Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title_fullStr Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title_full_unstemmed Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title_short Despite higher revision rate, MoM large-head THA offers better clinical scores than HR: 14-year results from a randomized controlled trial involving 48 patients
title_sort despite higher revision rate, mom large-head tha offers better clinical scores than hr: 14-year results from a randomized controlled trial involving 48 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091753/
https://www.ncbi.nlm.nih.gov/pubmed/33941155
http://dx.doi.org/10.1186/s12891-021-04286-6
work_keys_str_mv AT kostretzislazaros despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients
AT lavignemartin despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients
AT kissmarcolivier despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients
AT shahinmaged despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients
AT barryjanie despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients
AT vendittolipascalandre despitehigherrevisionratemomlargeheadthaoffersbetterclinicalscoresthanhr14yearresultsfromarandomizedcontrolledtrialinvolving48patients